CONCLUSIONS	O
:	O
The	O
combination	O
of	O
paclitaxel	B-Chemical
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	B-Chemical
is	O
well	O
tolerated	O
and	O
shows	O
high	O
activity	O
in	O
metastatic	O
NSCLC	B-Disease
.	O

Therefore	O
,	O
patients	O
with	O
glioblastoma	B-Disease
sometimes	O
have	O
intracarotid	O
injection	O
of	O
carcinostatics	O
added	O
to	O
the	O
treatment	O
regimen	O
.	O

These	O
results	O
suggest	O
that	O
the	O
facilitation	O
of	O
memory	O
retrieval	O
by	O
pre	O
-	O
test	O
morphine	B-Chemical
might	O
be	O
the	O
direct	O
action	O
of	O
morphine	B-Chemical
rather	O
than	O
a	O
state	O
dependent	O
effect	O
.	O

In	O
behavioral	O
studies	O
,	O
pre	O
-	O
treatment	O
of	O
mice	O
with	O
BD1018	B-Chemical
,	O
BD1063	B-Chemical
,	O
or	O
LR132	B-Chemical
significantly	O
attenuated	O
cocaine	B-Chemical
-	O
induced	O
convulsions	B-Disease
and	O
lethality	O
.	O

Twenty	O
-	O
three	O
h	O
postoperatively	O
he	O
developed	O
a	O
brief	O
self	O
-	O
limited	O
seizure	B-Disease
.	O

Moderate	O
abnormalities	O
require	O
a	O
reduction	O
of	O
deferoxamine	B-Chemical
to	O
25	O
mg	O
/	O
kg	O
per	O
dose	O
with	O
careful	O
monitoring	O
.	O

Following	O
instrumentation	O
,	O
halothane	B-Chemical
was	O
discontinued	O
and	O
alfentanil	B-Chemical
(	O
125	O
mu	O
/	O
kg	O
)	O
administered	O
iv	O
during	O
emergence	O
from	O
halothane	B-Chemical
anesthesia	O
.	O

To	O
this	O
end	O
,	O
doxorubicin	B-Chemical
(	O
15	O
mug	O
/	O
g	O
body	O
wt	O
)	O
was	O
injected	O
intravenously	O
into	O
gene	O
-	O
targeted	O
mice	O
lacking	O
SGK1	O
(	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
)	O
and	O
their	O
wild	O
-	O
type	O
littermates	O
(	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
)	O
.	O

Many	O
patients	O
,	O
however	O
,	O
develop	O
negative	O
long	O
-	O
term	O
side	O
effects	O
such	O
as	O
premature	B-Disease
atherosclerosis	I-Disease
.	O

PD	O
female	O
rats	O
also	O
showed	O
increased	O
(	O
3	O
)	O
H	B-Chemical
-	O
haloperidol	B-Chemical
binding	O
and	O
decreased	O
dopamine	B-Chemical
transporter	O
binding	O
in	O
striatum	O
.	O

Cardiomyopathy	B-Disease
is	O
frequent	O
when	O
the	O
total	O
dose	O
exceeds	O
600	O
mg	O
/	O
m2	O
and	O
occurs	O
within	O
one	O
to	O
six	O
months	O
after	O
cessation	O
of	O
therapy	O
.	O

An	O
experiment	O
was	O
performed	O
to	O
test	O
whether	O
inclusion	O
of	O
phenobarbital	B-Chemical
in	O
a	O
choline	B-Chemical
-	O
devoid	O
diet	O
would	O
increase	O
the	O
hepatocarcinogenicity	O
of	O
the	O
diet	O
.	O

Adverse	O
reactions	O
possibly	O
attributable	O
to	O
didanosine	B-Chemical
were	O
common	O
.	O

Thirty	O
-	O
six	O
patients	O
were	O
treated	O
with	O
BCNU	B-Chemical
every	O
6	O
to	O
8	O
weeks	O
,	O
either	O
by	O
transfemoral	O
catheterization	O
of	O
the	O
internal	O
carotid	O
or	O
vertebral	O
artery	O
or	O
through	O
a	O
fully	O
implantable	O
intracarotid	O
drug	O
delivery	O
system	O
,	O
beginning	O
with	O
a	O
dose	O
of	O
200	O
mg	O
/	O
sq	O
m	O
body	O
surface	O
area	O
.	O

Treatment	O
-	O
related	O
adverse	O
events	O
(	O
AEs	O
)	O
occurred	O
in	O
44	O
%	O
and	O
52	O
%	O
,	O
57	O
%	O
,	O
and	O
41	O
%	O
of	O
the	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperidol	B-Chemical
,	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O

Normalizing	O
effects	O
of	O
modafinil	B-Chemical
on	O
sleep	O
in	O
chronic	O
cocaine	B-Chemical
users	O
.	O

Inappropriate	O
use	O
of	O
carbamazepine	B-Chemical
and	O
vigabatrin	B-Chemical
in	O
typical	O
absence	B-Disease
seizures	I-Disease
.	O

Pregnant	O
rats	O
were	O
given	O
either	O
vehicle	O
or	O
2	O
daily	O
intraperitoneal	O
injections	O
of	O
dexamethasone	B-Chemical
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
on	O
gestational	O
days	O
11	O
and	O
12	O
,	O
13	O
and	O
14	O
,	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
or	O
19	O
and	O
20	O
.	O

The	O
pharmacological	O
challenge	O
data	O
suggest	O
that	O
tolerance	O
may	O
occur	O
to	O
seizure	B-Disease
activity	O
induced	O
by	O
PTZ	B-Chemical
and	O
PTX	B-Chemical
24	O
h	O
after	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
,	O
since	O
the	O
response	O
to	O
only	O
these	O
two	O
seizure	B-Disease
-	O
inducing	O
agents	O
is	O
decreased	O
.	O

International	O
mexiletine	B-Chemical
and	O
placebo	O
antiarrhythmic	O
coronary	O
trial	O
:	O
I	O
.	O

However	O
,	O
compression	B-Disease
neuropathy	I-Disease
due	O
to	O
fibrotic	O
muscle	O
affected	O
by	O
pentazocine	B-Chemical
-	O
induced	O
myopathy	B-Disease
has	O
not	O
previously	O
been	O
reported	O
.	O

These	O
results	O
indicate	O
a	O
reliable	O
memory	O
for	O
magnitude	O
and	O
duration	O
of	O
experimentally	O
induced	O
pain	B-Disease
.	O

What	O
is	O
less	O
well	O
known	O
is	O
a	O
phenomenon	O
whereby	O
statins	B-Chemical
may	O
induce	O
a	O
myopathy	B-Disease
,	O
which	O
persists	O
or	O
may	O
progress	O
after	O
stopping	O
the	O
drug	O
.	O

Eight	O
of	O
the	O
isolated	O
-	O
HIT	B-Disease
patients	O
developed	O
thrombosis	B-Disease
within	O
the	O
next	O
30	O
d	O
;	O
thus	O
,	O
a	O
total	O
of	O
48	O
patients	O
had	O
thrombosis	B-Disease
at	O
day	O
30	O
.	O

Adriamycinol	B-Chemical
,	O
doxorubicin	B-Chemical
,	O
adriamycinone	B-Chemical
,	O
and	O
tetrahydropyranyladriamycinol	B-Chemical
were	O
the	O
metabolites	O
detected	O
in	O
plasma	O
and	O
the	O
amount	O
of	O
doxorubicin	B-Chemical
was	O
less	O
than	O
or	O
equal	O
to	O
10	O
%	O
of	O
the	O
total	O
metabolites	O
.	O

Treatment	O
for	O
2	O
weeks	O
with	O
Warfarin	B-Chemical
caused	O
massive	O
focal	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	O
20	O
-	O
day	O
-	O
old	O
rats	O
and	O
less	O
extensive	O
focal	O
calcification	B-Disease
in	O
42	O
-	O
day	O
-	O
old	O
rats	O
.	O

Confusion	B-Disease
mostly	O
occurred	O
during	O
the	O
two	O
first	O
weeks	O
following	O
valproic	B-Chemical
acid	I-Chemical
exposure	O
(	O
39	O
.	O
7	O
%	O
)	O
.	O

Therefore	O
,	O
concomitant	O
administration	O
of	O
small	O
doses	O
of	O
bradykinin	B-Chemical
receptor	O
antagonists	O
and	O
NO	B-Chemical
synthase	O
inhibitors	O
can	O
be	O
effective	O
in	O
alleviation	O
of	O
neuropathic	B-Disease
pain	I-Disease
,	O
even	O
in	O
hospital	O
care	O
.	O

The	O
electrocardiograms	O
(	O
ECG	O
)	O
of	O
99	O
cocaine	B-Chemical
-	O
abusing	O
patients	O
were	O
compared	O
with	O
the	O
ECGs	O
of	O
50	O
schizophrenic	B-Disease
controls	O
.	O

RESULTS	O
:	O
We	O
report	O
seven	O
cases	O
where	O
substitution	O
of	O
lithium	B-Chemical
,	O
either	O
fully	O
or	O
partially	O
,	O
with	O
divalproex	B-Chemical
sodium	I-Chemical
was	O
extremely	O
helpful	O
in	O
reducing	O
the	O
cognitive	B-Disease
,	I-Disease
motivational	I-Disease
,	I-Disease
or	I-Disease
creative	I-Disease
deficits	I-Disease
attributed	O
to	O
lithium	B-Chemical
in	O
our	O
bipolar	B-Disease
patients	O
.	O

Anthracyclines	B-Chemical
are	O
effective	O
antineoplastic	O
drugs	O
,	O
but	O
they	O
frequently	O
cause	O
dose	O
-	O
related	O
cardiotoxicity	B-Disease
.	O

We	O
used	O
an	O
in	O
vitro	O
model	O
of	O
chemotherapy	O
induced	O
peripheral	B-Disease
neuropathy	I-Disease
that	O
closely	O
mimic	O
the	O
in	O
vivo	O
condition	O
by	O
exposing	O
primary	O
cultures	O
of	O
dorsal	O
root	O
ganglion	O
(	O
DRG	O
)	O
sensory	O
neurons	O
to	O
paclitaxel	B-Chemical
and	O
cisplatin	B-Chemical
,	O
two	O
widely	O
used	O
and	O
highly	O
effective	O
chemotherapeutic	O
drugs	O
.	O

Memory	O
retrieval	O
of	O
experiences	O
acquired	O
prior	O
to	O
cocaine	B-Chemical
administration	O
was	O
impaired	O
and	O
negatively	O
correlated	O
with	O
NFkappaB	O
activity	O
in	O
the	O
frontal	O
cortex	O
.	O

Proteinuria	B-Disease
was	O
measured	O
every	O
2	O
weeks	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
that	O
impairment	O
of	O
hepatocyte	O
TJs	O
occurs	O
heterogenously	O
in	O
the	O
liver	O
lobule	O
after	O
BDL	O
and	O
suggests	O
that	O
BDL	O
and	O
EE	B-Chemical
treatments	O
produce	O
different	O
lobular	O
distributions	O
of	O
increased	O
paracellular	O
permeability	O
.	O

As	O
no	O
other	O
medications	O
known	O
to	O
effect	O
serum	O
potassium	B-Chemical
had	O
been	O
given	O
concomitantly	O
,	O
this	O
course	O
of	O
events	O
is	O
suggestive	O
of	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
between	O
sulindac	B-Chemical
and	O
hyperkalemia	B-Disease
.	O

Differential	O
impact	O
of	O
immune	O
escape	O
mutations	O
G145R	O
and	O
P120T	O
on	O
the	O
replication	O
of	O
lamivudine	B-Chemical
-	O
resistant	O
hepatitis	B-Chemical
B	I-Chemical
virus	I-Chemical
e	I-Chemical
antigen	I-Chemical
-	O
positive	O
and	O
-	O
negative	O
strains	O
.	O

Myocardial	O
concentrations	O
of	O
calcium	B-Chemical
also	O
increased	O
significantly	O
(	O
12	O
.	O
0	O
vs	O
.	O
5	O
.	O
0	O
mg	O
.	O
per	O
100	O
Gm	O
.	O
of	O
fat	O
-	O
free	O
dry	O
weight	O
)	O
.	O

Because	O
of	O
the	O
need	O
for	O
the	O
development	O
of	O
new	O
treatments	O
for	O
Crohn	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
,	O
a	O
pilot	O
study	O
was	O
undertaken	O
to	O
estimate	O
the	O
pharmacodynamics	O
and	O
tolerability	O
of	O
fusidic	B-Chemical
acid	I-Chemical
treatment	O
in	O
chronic	O
active	O
,	O
therapy	O
-	O
resistant	O
patients	O
.	O

To	O
better	O
understand	O
the	O
utility	O
of	O
GLEPP1	O
as	O
a	O
marker	O
of	O
glomerular	B-Disease
injury	I-Disease
,	O
the	O
amount	O
and	O
distribution	O
of	O
GLEPP1	O
protein	O
and	O
mRNA	O
were	O
examined	O
by	O
immunohistochemistry	O
,	O
Western	O
blot	O
and	O
RNase	O
protection	O
assay	O
in	O
a	O
model	O
of	O
podocyte	O
injury	O
in	O
the	O
rat	O
.	O

